User contributions
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 18:01, 19 September 2022 (diff | hist) . . (0) . . m Curation Manual2.0 (→Host Organsim) (current)
- 16:45, 8 August 2022 (diff | hist) . . (+67) . . m CEDAR/Cancer Specific Rules (→Treatments) (current)
- 21:18, 20 July 2022 (diff | hist) . . (+270) . . m Curation Manual2.0 (→Modified Amino Acids)
- 21:02, 18 July 2022 (diff | hist) . . (+525) . . m CEDAR/Cancer Specific Rules (→Healthy Host)
- 19:56, 18 July 2022 (diff | hist) . . (+246) . . m Curation Manual2.0 (→Object Editor)
- 18:56, 22 June 2022 (diff | hist) . . (+797) . . m CEDAR/Cancer Specific Rules (→Animal Models of Cancer)
- 18:55, 22 June 2022 (diff | hist) . . (+32) . . m CEDAR/Cancer Specific Rules (→Animal Models of Cancer)
- 16:51, 22 June 2022 (diff | hist) . . (+335) . . m CEDAR/Cancer Specific Rules (→Animal Models of Cancer)
- 16:48, 22 June 2022 (diff | hist) . . (+8) . . m CEDAR/Cancer Specific Rules (→Animal Models of Cancer)
- 16:47, 22 June 2022 (diff | hist) . . (-2) . . m CEDAR/Cancer Specific Rules (→Animal Models of Cancer)
- 16:46, 22 June 2022 (diff | hist) . . (+46) . . m CEDAR/Cancer Specific Rules (→Animal Models of Cancer)
- 16:44, 22 June 2022 (diff | hist) . . (+449) . . m CEDAR/Cancer Specific Rules (→Healthy Host)
- 23:04, 13 June 2022 (diff | hist) . . (-289) . . m CEDAR/Cancer Specific Rules (→Neoepitopes)
- 18:49, 5 April 2022 (diff | hist) . . (-328) . . m Curation Manual2.0 (→Antigen Presenting Cells)
- 18:44, 5 April 2022 (diff | hist) . . (+244) . . m Curation Manual2.0 (→In vivo Process)
- 18:42, 5 April 2022 (diff | hist) . . (+561) . . m Curation Manual2.0 (→Antigen Presenting Cells)
- 18:40, 5 April 2022 (diff | hist) . . (+631) . . m Curation Manual2.0 (→Antigen Presenting Cells)
- 17:17, 5 April 2022 (diff | hist) . . (+13) . . m Curation Manual2.0 (→MHC Allele)
- 17:16, 5 April 2022 (diff | hist) . . (+98) . . m Curation Manual2.0 (→MHC Allele)
- 17:13, 5 April 2022 (diff | hist) . . (+542) . . m Curation Manual2.0 (→MHC Allele)
- 17:05, 5 April 2022 (diff | hist) . . (+7) . . m Curation Manual2.0 (→Ligand Elution Assay Types)
- 17:04, 5 April 2022 (diff | hist) . . (+260) . . m Curation Manual2.0 (→Ligand Elution Assay Types)
- 19:13, 4 April 2022 (diff | hist) . . (+79) . . m Curation Manual2.0 (→MHC Ligand Elution Fields)
- 19:12, 4 April 2022 (diff | hist) . . (-2) . . m Curation Manual2.0 (→MHC Ligand Elution Fields)
- 19:12, 4 April 2022 (diff | hist) . . (+214) . . m Curation Manual2.0 (→MHC Ligand Elution Fields)
- 18:31, 30 March 2022 (diff | hist) . . (+392) . . m Curation Manual2.0 (→Helpful Websites)
- 23:03, 2 March 2022 (diff | hist) . . (+1) . . m Disease Specific Rules (→Coronavirus) (current)
- 23:03, 2 March 2022 (diff | hist) . . (+3) . . m Disease Specific Rules (→Coronavirus)
- 23:03, 2 March 2022 (diff | hist) . . (+559) . . m Disease Specific Rules (→Coronavirus)
- 17:04, 2 March 2022 (diff | hist) . . (+752) . . m Curation Manual2.0 (→Modified Amino Acids)
- 00:04, 4 February 2022 (diff | hist) . . (+2) . . m Curation Manual2.0 (→Competition/Inhibition Assays)
- 00:03, 4 February 2022 (diff | hist) . . (+2) . . m Curation Manual2.0 (→Challenge Assays)
- 00:03, 4 February 2022 (diff | hist) . . (+295) . . m Curation Manual2.0 (→Antibody Display Libraries)
- 00:01, 4 February 2022 (diff | hist) . . (+290) . . m Curation Manual2.0 (→Assayed Antibody)
- 00:00, 4 February 2022 (diff | hist) . . (+1) . . m Curation Manual2.0 (→Presence of Epitope)
- 00:00, 4 February 2022 (diff | hist) . . (-3) . . m Curation Manual2.0 (→Presence of Epitope)
- 23:59, 3 February 2022 (diff | hist) . . (+569) . . m Curation Manual2.0 (→Presence of Epitope)
- 23:54, 3 February 2022 (diff | hist) . . (+277) . . m CEDAR/Cancer Specific Rules (→Negative Monoclonal Responses)
- 01:03, 27 January 2022 (diff | hist) . . (-4) . . m Data Field Descriptions (→Guidelines on Adoptive Transfer) (current)
- 22:47, 26 January 2022 (diff | hist) . . (+6) . . m Data Field Descriptions (→Guidelines on B cell Assays)
- 22:47, 26 January 2022 (diff | hist) . . (+16) . . m Data Field Descriptions (→Guidelines on Adoptive Transfer)
- 17:55, 26 January 2022 (diff | hist) . . (+1) . . m Curation Manual2.0 (→In vitro Process)
- 17:54, 26 January 2022 (diff | hist) . . (+333) . . m Curation Manual2.0 (→In vitro Process)
- 17:50, 26 January 2022 (diff | hist) . . (+59) . . m Curation Manual2.0 (→In vivo Process)
- 17:47, 26 January 2022 (diff | hist) . . (+91) . . m Curation Manual2.0 (→In vitro Process)
- 17:46, 26 January 2022 (diff | hist) . . (+76) . . m Curation Manual2.0 (→In vivo Process)
- 17:43, 26 January 2022 (diff | hist) . . (+519) . . m Disease Specific Rules (→Allergy)
- 17:30, 26 January 2022 (diff | hist) . . (+324) . . m Curation Manual2.0 (→Add MHC Ligand Elution)
- 17:25, 26 January 2022 (diff | hist) . . (+253) . . m Curation Manual2.0 (→MHC Ligand Elution Fields)
- 17:20, 26 January 2022 (diff | hist) . . (+271) . . m Curation Manual2.0 (→Add MHC Ligand Elution)
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
